BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28591716)

  • 1. Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
    Prabhu L; Wei H; Chen L; Demir Ö; Sandusky G; Sun E; Wang J; Mo J; Zeng L; Fishel M; Safa A; Amaro R; Korc M; Zhang ZY; Lu T
    Oncotarget; 2017 Jun; 8(25):39963-39977. PubMed ID: 28591716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
    Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
    Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRMT5 is a therapeutic target in choroidal neovascularization.
    Muniyandi A; Martin M; Sishtla K; Motolani A; Sun M; Jensen NR; Qi X; Boulton ME; Prabhu L; Lu T; Corson TW
    Sci Rep; 2023 Jan; 13(1):1747. PubMed ID: 36720900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
    Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
    Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
    Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
    Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
    [No Abstract]   [Full Text] [Related]  

  • 6. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
    Orben F; Lankes K; Schneeweis C; Hassan Z; Jakubowsky H; Krauß L; Boniolo F; Schneider C; Schäfer A; Murr J; Schlag C; Kong B; Öllinger R; Wang C; Beyer G; Mahajan UM; Xue Y; Mayerle J; Schmid RM; Kuster B; Rad R; Braun CJ; Wirth M; Reichert M; Saur D; Schneider G
    JCI Insight; 2022 May; 7(10):. PubMed ID: 35439169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of a PRMT5/NF-κB Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer.
    Hartley AV; Wang B; Jiang G; Wei H; Sun M; Prabhu L; Martin M; Safa A; Sun S; Liu Y; Lu T
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
    Zhu K; Jiang C; Tao H; Liu J; Zhang H; Luo C
    Bioorg Med Chem Lett; 2018 May; 28(9):1476-1483. PubMed ID: 29628326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRMT5 promotes colorectal cancer growth by interaction with MCM7.
    Li X; Wang X; Zhao J; Wang J; Wu J
    J Cell Mol Med; 2021 Apr; 25(7):3537-3547. PubMed ID: 33675123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3β signaling cascades.
    Yan Y; Zhao P; Wang Z; Liu Z; Wang Z; Zhang J; Ding Y; Hua X; Yu L
    Aging (Albany NY); 2021 Jan; 13(3):4468-4481. PubMed ID: 33495409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
    Wei X; Yang J; Adair SJ; Ozturk H; Kuscu C; Lee KY; Kane WJ; O'Hara PE; Liu D; Demirlenk YM; Habieb AH; Yilmaz E; Dutta A; Bauer TW; Adli M
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28068-28079. PubMed ID: 33097661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation.
    Ge S; Zhang Q; Chen Y; Tian Y; Yang R; Chen X; Li F; Zhang B
    Toxicol Appl Pharmacol; 2021 Mar; 415():115450. PubMed ID: 33577917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
    Alinari L; Mahasenan KV; Yan F; Karkhanis V; Chung JH; Smith EM; Quinion C; Smith PL; Kim L; Patton JT; Lapalombella R; Yu B; Wu Y; Roy S; De Leo A; Pileri S; Agostinelli C; Ayers L; Bradner JE; Chen-Kiang S; Elemento O; Motiwala T; Majumder S; Byrd JC; Jacob S; Sif S; Li C; Baiocchi RA
    Blood; 2015 Apr; 125(16):2530-43. PubMed ID: 25742700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRMT5-mediated methylation of YBX1 regulates NF-κB activity in colorectal cancer.
    Hartley AV; Wang B; Mundade R; Jiang G; Sun M; Wei H; Sun S; Liu Y; Lu T
    Sci Rep; 2020 Sep; 10(1):15934. PubMed ID: 32985589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.
    Giuliani V; Miller MA; Liu CY; Hartono SR; Class CA; Bristow CA; Suzuki E; Sanz LA; Gao G; Gay JP; Feng N; Rose JL; Tomihara H; Daniele JR; Peoples MD; Bardenhagen JP; Geck Do MK; Chang QE; Vangamudi B; Vellano C; Ying H; Deem AK; Do KA; Genovese G; Marszalek JR; Kovacs JJ; Kim M; Fleming JB; Guccione E; Viale A; Maitra A; Emilia Di Francesco M; Yap TA; Jones P; Draetta G; Carugo A; Chedin F; Heffernan TP
    Nat Commun; 2021 Jul; 12(1):4626. PubMed ID: 34330913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NAA40 contributes to colorectal cancer growth by controlling PRMT5 expression.
    Demetriadou C; Pavlou D; Mpekris F; Achilleos C; Stylianopoulos T; Zaravinos A; Papageorgis P; Kirmizis A
    Cell Death Dis; 2019 Mar; 10(3):236. PubMed ID: 30858358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
    Ye F; Zhang W; Ye X; Jin J; Lv Z; Luo C
    J Chem Inf Model; 2018 May; 58(5):1066-1073. PubMed ID: 29672052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
    Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
    J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
    Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY
    Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.